Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05118425
Other study ID # XijingH-PF-20210220
Secondary ID
Status Completed
Phase
First received
Last updated
Start date November 1, 2020
Est. completion date September 1, 2021

Study information

Verified date November 2021
Source Xijing Hospital
Contact n/a
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

The influences of diet on psoriasis have been long discussed. As reported in previous publications, a majority of U.S. psoriasis population show high interest in the role of diet on their skin conditions. Given the distinct traditional perceptions and lifestyles in China, the dietary beliefs and behaviors in Chinese psoriasis patients would be very likely to show different patterns. Nevertheless, the information of this large population is still unknown. In this regard, the investigators conduct a questionnaire-based survey, aiming to assess the dietary perceptions and behaviors of Chinese psoriasis patients.


Description:

A total of 25 medical institutions all over China participated in the survey. Psoriasis patients surveyed were from both outpatient and inpatient dermatology departments. Researchers from each institution were trained for assisting patients to fill the questionnaire. Each participant filled the online-based questionnaire anonymously in a private setting. The questionnaire consisted of 54 main questions and extended questions, concerning the profile of disease conditions, perceptions and behaviors of diet in their daily life.


Recruitment information / eligibility

Status Completed
Enrollment 3453
Est. completion date September 1, 2021
Est. primary completion date June 1, 2021
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria: - Age = 18 years old. - Confirmed diagnosis of psoriasis. - Duration of psoriasis = 3 years. - Must be able to read and understand the questionnaire. - Receive a full explanation of the purpose and content of the trial before the study begins, and voluntarily sign a written consent form. Exclusion Criteria: - Unable to read or understand the questionnaire. - Other conditions deemed by the investigator to be inappropriate for this study.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Dermatology Derpartment of Xijing Hospital Xi'an Shaanxi

Sponsors (1)

Lead Sponsor Collaborator
Xijing Hospital

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Primary Practices of food choice in Chinese psoriasis patients. The cross-sectional study design consisting of a questionnaire survey. We conducted a cross-sectional study through Chinese Umer Doctor and WeChat platforms. The survey is a national program of studies aimed to evaluate the perception of nutrition in Chinese psoriasis patients over the age of 18 and its impact on disease. A total of 25 medical institutions participated in the survey, and the patient population covered 31 provinces and 241 cities. A specific self-administered questionnaire was designed for this study to be administered electronically to all patients. The questionnaire includes 54 main questions and extended questions, 15 items refer to the demographic and disease characteristics, 28 items refer to the dietary practices (eg. avoiding or adding certain food or dietary supplements), the the outcomes of the intervention, as well as factors related to different dietary practices. Information collection: over a span of 2 months
Secondary Perceptions of the correlation between diet choice and disease severity in Chinese psoriasis patients. 10 questions in the questionnaire was designed to detect the perceptions of the influence of dietary modification in patients conducting different dietary practices and the factors related to different perceptions. Information collection: over a span of 2 months
See also
  Status Clinical Trial Phase
Completed NCT03236870 - A Study to Evaluate the Effectiveness and Patient-Reported Outcome of Adalimumab in Patients With Moderate to Severe Plaque Psoriasis in China
Completed NCT00078819 - Etanercept (Enbrel®) in Psoriasis - Pediatrics Phase 3
Completed NCT04841187 - Assessing the Long Term Effectiveness and Safety of Systemic Treatments in Cutaneous Psoriasis
Active, not recruiting NCT03927352 - The Purpose of This Research Study is to Compare the Efficacy and Safety of SCT630 and Adalimumab (HUMIRA®) in Adults With Plaque Psoriasis Phase 3
Completed NCT03284879 - Post-Marketing Surveillance Study of OTEZLA
Recruiting NCT06027034 - Effectiveness of a Digital Health Application for Psoriasis N/A
Not yet recruiting NCT06050330 - CD4+ T Cells and S100A7 Epression in Normal and Psoriatic Skin: A Histological and Histochemical Study N/A
Recruiting NCT05744466 - A Real-world Observational Study to Compare Effectiveness of Deucravacitinib Vs Apremilast in Adults With Plaque Psoriasis
Completed NCT04149587 - A Study of Brodalumab (SILIQ®) in Psoriasis Participants With Inadequate Response to Their Current Biologic Agent Regimen
Completed NCT01384630 - Safety, Pharmacokinetics, and Efficacy of RA-18C3 in Subjects With Moderate to Severe Psoriasis Phase 2
Completed NCT03998683 - A Study of Guselkumab for the Treatment of Palmoplantar-non-Pustular Psoriasis Phase 3
Terminated NCT03556202 - A Long-term Study to Evaluate Safety and Maintenance of Treatment Effect of LY3074828 in Participants With Moderate-to-Severe Plaque Psoriasis (OASIS-3) Phase 3
Completed NCT05051943 - A Study of the Real-world Use of an Adalimumab Biosimilar and Evaluation of Nutritional Status on the Therapeutic Response
Recruiting NCT06077331 - A Study to Evaluate Efficacy and Safety of HS-10374 for Moderate to Severe Plaque Psoriasis Phase 2
Completed NCT04316585 - A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants Phase 1
Completed NCT04894890 - A Prospective Multicenter Study for the Assessment of Treatment Patterns, Effectiveness and Safety of Secukinumab in Adult Patients With Moderate to Severe Plaque Psoriasis in a Real-world Setting in China
Completed NCT00358384 - Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034 Phase 1
Completed NCT03757013 - A Study to Assess Benefits of Apremilast in Patients With Moderate to Severe Chronic Plaque Psoriasis Followed by Dermatologists Under Real Life Settings in France
Completed NCT03265613 - Safety and Efficacy of Expanded Allogeneic AD-MSCs in Patients With Moderate to Severe Psoriasis Phase 1/Phase 2
Completed NCT05003531 - A Study to Evaluate IBI112 in the Treatment of Subjects With Moderate to Severe Plaque Psoriasis Phase 2